Iceland· IS-EU/1/18/1340/001-003
Takhzyro
A lanadelumab product containing lanadelumabum inn, registered in Iceland by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 15 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Lanadelumab is registered in 15 of 19 countries.
Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Lanadelumab · ATC B06AC05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lanadelumab costs, country by country.
Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lanadelumab · price per daily dose (21.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$857.11
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Lanadelumabum INN
- Manufacturer
- Takeda Pharmaceuticals International AG Ireland Branch
- Country
- Iceland (IS)
- ATC code
- B06AC05
- ATC class
- Lanadelumab
- Defined daily dose
- 21.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 2
2 priced- ean1221292 ml x1 áfsprISK 2185357
- ean5360732 ml x1 áfpenISK 2185357
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lanadelumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTAKHZYROTakeda Pharmaceuticals International AG Ireland Branch, Dublin
- BelgiumTakhzyro 300 mgTakeda Pharmaceuticals International Ireland Branch
- SwedenTAKHZYRO 300 mg Injektionsvätska, lösningTakeda Pharmaceuticals International AG Ireland Branch
- SpainTAKHZYRO 300 MG SOLUCION INYECTABLETakeda Pharmaceuticals International Ag Ireland Branch
- NorwayTakhzyroTakeda Pharmaceuticals International AG Ireland Branch
- PolandTakhzyroTakeda Pharmaceuticals International AG
- United StatesTAKHZYROTakeda Pharmaceuticals America, Inc.
- FinlandTakhzyroOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Takhzyro
- Norway · Takhzyro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/873b91bb-536c-4593-a419-1d7269f590f5 GET /v1/drugs/873b91bb-536c-4593-a419-1d7269f590f5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn",
"source": "lyfjastofnun",
"atc_raw": "B06AC05",
"marketed": true,
"strength": "300 mg",
"ma_number": "EU/1/18/1340/001-003",
"substance": "Lanadelumabum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í ofnæmissjúkdómum, ónæmissjúkdómum og ofnæmis- og ónæmissjúkdómum barna.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "43426"
}See everything about lanadelumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.